
Profitability, historical returns, and peer comparisons.
According to Amgen Inc.’s latest financial reports and current stock price. The company's current ROE is 89.32%. This represents a change of 301.68% compared to the average of 22.24% of the last 4 quarters.
The mean historical ROE of Amgen Inc. over the last ten years is 79.25%. The current 89.32% ROE has changed 12.71% with respect to the historical average. Over the past ten years (40 quarters), AMGN.TO's ROE was at its highest in in the March 2022 quarter at 161.14%. The ROE was at its lowest in in the December 2017 quarter at -16.89%.
Average
79.25%
Median
79.14%
Minimum
7.84%
Maximum
178.97%
Discovering the peaks and valleys of Amgen Inc. ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 756.48%
Maximum Annual ROE = 178.97%
Minimum Annual Increase = -69.67%
Minimum Annual ROE = 7.84%
| Year | ROE | Change |
|---|---|---|
| 2025 | 89.06% | 27.98% |
| 2024 | 69.59% | -35.43% |
| 2023 | 107.78% | -39.78% |
| 2022 | 178.97% | 103.48% |
| 2021 | 87.96% | 13.93% |
| 2020 | 77.20% | -4.77% |
| 2019 | 81.07% | 20.73% |
| 2018 | 67.15% | 756.48% |
| 2017 | 7.84% | -69.67% |
| 2016 | 25.85% | 4.61% |
The current ROE of Amgen Inc. (AMGN.TO) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages
3-year avg
88.81%
5-year avg
106.67%
10-year avg
79.25%
Amgen Inc.’s ROE is less than Novartis AG (29.64%), greater than AbbVie Inc. (-136.50%), less than Johnson & Johnson (19.55%), less than Sanofi (5.52%), less than Novo Nordisk A/S (59.09%), less than Eli Lilly and Company (92.58%), greater than Gilead Sciences, Inc. (0%), less than Merck & Co., Inc. (6.60%), less than Biogen Inc. (4.52%), less than Pfizer Inc. (4.89%),
| Company | ROE | Market cap |
|---|---|---|
| 29.64% | $54.39B | |
| -136.50% | $69.98B | |
| 19.55% | $833.00B | |
| 5.52% | $22.83B | |
| 59.09% | $56.75B | |
| 92.58% | $1.57T | |
| 0% | $270.73B | |
| 6.60% | $79.57B | |
| 4.52% | $37.04B | |
| 4.89% | $75.92B |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Amgen Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Amgen Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the ROE?
How can you use the ROE?
What is Amgen Inc.'s ROE?
How is the ROE calculated for Amgen Inc. (AMGN.TO)?
What is the highest ROE for Amgen Inc. (AMGN.TO)?
What is the 3-year average ROE for Amgen Inc. (AMGN.TO)?
What is the 5-year average ROE for Amgen Inc. (AMGN.TO)?
How does the current ROE for Amgen Inc. (AMGN.TO) compare to its historical average?